Gossamer Bio Inc. (NASDAQ:GOSS) Faces Market Challenges Despite Potential in PAH Treatment
Gossamer Bio(US:GOSS) Financial Modeling Prep·2026-02-24 10:08Leerink Partners sets a price target of $1 for Gossamer Bio Inc. (NASDAQ:GOSS), suggesting a potential increase of about 63.76%.The company's Phase 3 PROSERA study on seralutinib for PAH showed potential efficacy but missed a key statistical threshold.Gossamer Bio's stock has experienced a significant decrease, currently priced at $0.42, reflecting an 80.13% decrease in value.Gossamer Bio Inc. (NASDAQ:GOSS) is a biopharmaceutical company focused on developing treatments for pulmonary arterial hypertension ( ...